A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Public ClinicalTrials.gov record NCT06131372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, semaglutide, cagrilintide or placebo. Which treatment participant will get is decided by chance (like flipping a coin). Study doctor will not know which of the study medicines participant will get. For each participant, the study will last for about 35 weeks.
Study identification
- NCT ID
- NCT06131372
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 626 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1, 2024 (Actual)
- Primary completion
- Sep 24, 2025 (Actual)
- Completion
- Nov 6, 2025 (Actual)
- Last update posted
- Sep 24, 2026
2024 – 2025
United States locations
- U.S. sites
- 25
- U.S. states
- 12
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| John Muir Physicians Network | Concord | California | 94520 | — |
| Valley Research | Fresno | California | 93720 | — |
| Desert Oasis Hlthcr Med Group | Palm Springs | California | 92262 | — |
| North America Research Institute | San Dimas | California | 91773 | — |
| NorCal Endocrinology and Internal Medicine | San Ramon | California | 94583 | — |
| Northeast Research Institute | Fleming Island | Florida | 32003 | — |
| Life Spring Research Foundation LLC | Miami | Florida | 33130 | — |
| Advent Health Translational Research Institute | Orlando | Florida | 32804 | — |
| Velocity Clin. Res Valparaiso | Valparaiso | Indiana | 46383 | — |
| Elite Research Center | Flint | Michigan | 48532 | — |
| Univ. of Nebraska Medical Center_Omaha | Omaha | Nebraska | 68198 | — |
| Albany Medical College | Albany | New York | 12203 | — |
| NYU Langone Nephrology Associates | Mineola | New York | 11501 | — |
| New York University Grossman School of Medicine | New York | New York | 10016 | — |
| Southgate Medical Group, LLP | West Seneca | New York | 14224 | — |
| Carteret Medical Group | Morehead City | North Carolina | 28557 | — |
| Eastern Nephrology Associates, PLLC | New Bern | North Carolina | 28562 | — |
| Brookview Hills Research Associates, LLC | Winston-Salem | North Carolina | 27103 | — |
| Ohio- Advanced Medical Research | Maumee | Ohio | 43537 | — |
| Heritage Valley Multispeciality Group Inc | Beaver | Pennsylvania | 15009 | — |
| Main Street Physician's Care | Little River | South Carolina | 29566 | — |
| Osvaldo A. Brusco MD | Corpus Christi | Texas | 78414 | — |
| Southwest Houston Research Ltd | Houston | Texas | 77099 | — |
| Clinical Advancement Center | San Antonio | Texas | 78212 | — |
| Clinical Investigation Specialists Inc, Kenosha | Kenosha | Wisconsin | 53144 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06131372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06131372 live on ClinicalTrials.gov.